Cerebral autoregulation (CA) as a mechanism to protect the brain from ischemia or hypoperfusion may play an important role related to post-stroke interventions such as the physiotherapy and the outcome. Here, we present a non-invasive assessment of the CA status by diffuse correlation spectroscopy (DCS) measures calculating the DCS moving correlation coeffcient CBFx with arterial blood pressure (ABP). The measurements are performed during the first mobilization after the onset of the symptoms. The CBFx is compared to values obtained in a healthy population showing signicantly higher values in the stroke population. This may pave the way for personalized treatment.
A limiting factor for personalizing therapies in stroke patients is the inability to continuously monitor the cerebral status of patients. In particular, potential impairment of cerebral autoregulation (CA) in these patients may incur certain risks during their mobilization. We have used hybrid diffuse optical techniques to measure new biomarkers related to CA status as well as metabolic health in a large cohort of stroke patients in order to determine biomarkers indicative of clinical improvement. If validated, these results can pave the way towards personalization of stroke therapy based on direct measures of cerebral health.
Access to the requested content is limited to institutions that have purchased or subscribe to SPIE eBooks.
You are receiving this notice because your organization may not have SPIE eBooks access.*
*Shibboleth/Open Athens users─please
sign in
to access your institution's subscriptions.
To obtain this item, you may purchase the complete book in print or electronic format on
SPIE.org.
INSTITUTIONAL Select your institution to access the SPIE Digital Library.
PERSONAL Sign in with your SPIE account to access your personal subscriptions or to use specific features such as save to my library, sign up for alerts, save searches, etc.